Zymeworks raises 2026 guidance after $250M Ziihera milestone, posts Roche deal for ZW209
Zymeworks reported third-quarter 2026 results, raised full-year revenue and EBITDA guidance, and detailed a new Roche collaboration on ZW209 pending antitrust clearance.
SEC filing